首页 | 官方网站   微博 | 高级检索  
     

磷酸奥司他韦干混悬剂的人体药动学与生物等效性
引用本文:冯婉妮,金娟,朱昌海,王欣桐,周玲,彭杰敏,甘方良.磷酸奥司他韦干混悬剂的人体药动学与生物等效性[J].中国医院药学杂志,2023,43(5):519-524.
作者姓名:冯婉妮  金娟  朱昌海  王欣桐  周玲  彭杰敏  甘方良
作者单位:1. 湖北科技学院附属第一医院临床药理研究中心, 湖北 咸宁 437100;2. 复杂基质样本生物分析湖南省重点实验室, 湖南 长沙 410000
摘    要:目的:研究磷酸奥司他韦干混悬剂在健康受试者的人体药动学和生物等效性。方法:78例受试者分别空腹和餐后口服75 mg受试制剂或参比制剂。采用高效液相色谱-串联质谱(HPLC-MS/MS)检测奥司他韦和奥司他韦酸的全血浓度,用WinNonlin 8.2软件计算药动学参数,评价两制剂生物等效性。结果:空腹试验受试制剂和参比制剂的奥司他韦Cmax、AUC0-t、AUC0-∞分别为(52.07±23.44)和(50.54±16.09)ng·mL-1、(150.8±32.0)和(153.6±29.3)h·ng·mL-1、(154.2±32.2)和(157.8±30.9)h·ng·mL-1;奥司他韦羧酸盐Cmax、AUC0-t、AUC0-∞分别为(259.66±42.65)和(267.10±44.06)ng·mL-1、(3 235.1±549.9)和(3 321.6±567.5)h·...

关 键 词:奥司他韦  生物等效性  药动学  干混悬剂
收稿时间:2022-04-20

Pharmacokinetics and bioequivalence study of oseltamivir phosphate dry suspension in healthy Chinese subjects
FENG Wan-ni,JIN Juan,ZHU Chang-hai,WANG Xin-tong,ZHOU Ling,PENG Jie-min,GAN Fang-liang.Pharmacokinetics and bioequivalence study of oseltamivir phosphate dry suspension in healthy Chinese subjects[J].Chinese Journal of Hospital Pharmacy,2023,43(5):519-524.
Authors:FENG Wan-ni  JIN Juan  ZHU Chang-hai  WANG Xin-tong  ZHOU Ling  PENG Jie-min  GAN Fang-liang
Affiliation:1. Clinical Pharmacology Research Center, First Affiliated Hospital of Hubei University of Science and Technology, Hubei Xianning 437100, China;2. Hunan Provincial Key Laboratory for Bioanalysis of Complex Matrix Samples, Hunan Changsha 410000, China
Abstract:OBJECTIVE To study the pharmacokinetics and bioequivalence of test preparation and reference preparation of oseltamivir phosphate dry suspension in healthy volunteers under fasted and fed conditions.METHODS Totally 78 subjects were orally administered 75 mg of the test preparation or the reference preparation under fasted and fed, respectively. High performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to detect the whole blood concentration of oseltamivir and oseltamivir acid, and WinNonlin 8.2 software was used to calculate the pharmacokinetic parameters and evaluate the bioequivalence of the two preparations.RESULTS The major pharmacokinetic parameters of the test and reference oseltamivir under the fasted condition were as follows: Cmax(52.07±23.44) and (50.54±16.09)ng·mL-1, AUC0-t(150.8±32.0) and (153.6±29.3) h·ng·mL-1, AUC0-∞(154.2±32.2) and (157.8±30.9) h·ng·mL-1. The major pharmacokinetic parameters of the test and reference oseltamivir carboxylate under the fasted condition were as follows: Cmax(259.66±42.65) and (267.10±44.06)ng·mL-1, AUC0-t(3 235.1±549.9) and(3 321.6±567.5) h·ng·mL-1, AUC0-∞(3 284.2±564.9) and(3 372.4±593.5)h·ng·mL-1. The major pharmacokinetic parameters of the test and reference oseltamivir in the fed condition were as follows: Cmax(40.56±10.72) and (38.82±10.98)ng·mL-1,AUC0-t(145.4±24.5) and (145.3±28.7)h·ng·mL-1,AUC0-∞(151.2±25.4) and (149.0±28.5)h·ng·mL-1. The major pharmacokinetic parameters of the test and reference oseltamivir carboxylate in the fed condition were as follows: Cmax(198.12±34.65) and (199.56±36.39)ng·mL-1, AUC0-t(2 794.8±373.2) and (2 828.1±416.5)h·ng·mL-1, AUC0-∞(2 853.0±383.4) and (2 885.9±423.2)h·ng·mL-1.CONCLUSION The 90%CI of the geometric mean ratios of the test preparation and the reference preparation for the Cmax, AUC0-t and AUC0-∞ of oseltamivir and oseltamivir acid under the fasted and fed conditions is within the range of 80%-125%, suggesting the two preparations are bioequivalent.
Keywords:oseltamivir  bioequivalence  pharmacokinetics  dry suspension  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号